Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing Acute Pulmonary Embolism After Off-Pump Coronary Artery Bypass Surgery Using a Predictive XGBoost Model.

Journal of multidisciplinary healthcare·2026
Same author

Molecularly Engineered PVDF-HFP Electrolyte with PVDC Analog for High-Performance Solid-State Lithium Metal Batteries.

ACS applied materials & interfaces·2026
Same author

Pretreatment steroids and delayed intervention predict poor long-term outcomes in spinal dural arteriovenous fistulas: a cohort study.

Journal of neurointerventional surgery·2026
Same author

Noninvasive Volume Measurement of Cerebral Arteriovenous Malformation Nidus: Silent MRA Compared with TOF-MRA.

AJNR. American journal of neuroradiology·2026
Same author

Study on the effect and mechanism of sesamin on P2X3-related cheek allergic contact dermatitis in mice induced by SADBE stimulation.

Neuropharmacology·2026
Same author

Hypericin alleviates high glucose-induced ferroptosis in cultured rat satellite glial cells via targeting P2X7R to activate the Akt/GSK3β/Nrf2 axis.

Neuropharmacology·2026

Related Experiment Video

Updated: May 24, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury

Shuangmei Liu1, Changshui Xu, Guilin Li

  • 1Department of Physiology, Medical College of Nanchang University, Nanchang, Jiangxi 330006, PR China.

Neurochemistry International
|February 25, 2012
PubMed
Summary

Vatalanib, a VEGF receptor-2 inhibitor, alleviates neuropathic pain in rats by reducing the interaction between VEGFR-2 and P2X(2/3) receptors in dorsal root ganglia. This study highlights a novel therapeutic target for managing chronic pain conditions.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

Related Experiment Videos

Last Updated: May 24, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Neuropathic pain, stemming from peripheral nervous system lesions, significantly impacts quality of life.
  • Selective antagonists for P2X(3) and P2X(2/3) receptors and VEGF inhibitors show promise in pain management.
  • The interaction between Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) and P2X(2/3) receptors in neuropathic pain remains to be fully elucidated.

Purpose of the Study:

  • To investigate the therapeutic effects of Vatalanib, a VEGFR-2 inhibitor, on neuropathic pain in a rat model.
  • To explore the interaction between VEGFR-2 and P2X(2/3) receptors in the dorsal root ganglia (DRG) of rats with chronic constriction injury (CCI).

Main Methods:

  • Establishment of a CCI rat model to induce neuropathic pain, with groups including sham, CCI, and Vatalanib-treated CCI rats.
  • Assessment of pain behaviors using mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) tests.
  • Detection of VEGFR-2 and P2X(2)/P2X(3) receptor co-expression in DRG via immunofluorescence and analysis of VEGF modulation on receptor activity using whole-cell patch-clamp recordings.

Main Results:

  • CCI rats exhibited significantly reduced MWT and TWL compared to sham rats, indicating neuropathic pain.
  • Vatalanib treatment significantly improved MWT and TWL in CCI rats, alleviating pain symptoms.
  • VEGFR-2 and P2X(2)/P2X(3) receptors were co-expressed in DRG, with increased co-expression observed in CCI rats. Vatalanib treatment reduced this co-expression and blocked VEGF-enhanced receptor activity.

Conclusions:

  • Vatalanib effectively alleviates chronic neuropathic pain in rats.
  • The therapeutic effect of Vatalanib is associated with the inhibition of VEGFR-2 activation and the disruption of the interaction between VEGFR-2 and P2X(2/3) receptors.
  • Targeting the VEGFR-2 and P2X(2/3) receptor pathway presents a potential strategy for managing neuropathic pain.